TaiGen Biotechnology Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TaiGen Biotechnology Co., Ltd.
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.